Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clasp Launches With $150m To Develop Personalized T-Cell Engagers

Dual Agents Target Oncogenes And HLA Proteins

Executive Summary

Clasp Therapeutics, which emerged from labs at Johns Hopkins University and was incubated by a pair of venture capital investors, plans to achieve a clinical trial readout with its series A cash.

You may also be interested in...



Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan

Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A. 

Transforming Coherus Adds To IO Pipeline Via Merger With Surface Oncology

Currently battling AbbVie over pricing plans for its Humira biosimilar, Coherus is also looking to become an immuno-oncology player, acquiring two more clinical assets in an all-stock deal.

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel